Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT03501576
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Inactivated Influenza Vaccine — BIOLOGICAL
    Given seasonal inactivated influenza vaccine IM

Study Details

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.

Key Dates

Start date
Apr 6, 2018
Status verified
Feb 2026
Primary completion
May 26, 2026
Completion
May 26, 2026

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Inactivated Influenza Vaccine
    Patients will be vaccinated with an FDA approved seasonal inactivated influenza vaccine
  • Arm: Qualifying subjects to receive a SARS-CoV2 vaccine.
    Patients receive a SARS-CoV2 vaccine.
  • Arm: Clinical Group Receiving SARS-CoV2 Booster Vaccines
    Patients receive a SARS-CoV2 vaccine.

Primary Outcome Measure

Cohort 1: Percentage of subjects achieving seroprotection, defined as the percentage of subjects with a post-vaccination HI titer > 1:40 [ Time Frame: Up to 180 days after immunization ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Emory University Hospital MidtownAtlantaGeorgia30308
Michael Churnetski
404-778-3703
Andres Chang, MD, PhD (PRINCIPAL_INVESTIGATOR)
Emory University Hospital/Winship Cancer InstituteAtlantaGeorgia30322
Mike Churnetski
404-778-3703
Vanessa Smith
404-778-2419

Find similar trials in Atlanta, GA

By condition

Related Studies